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ABSTRACT
Questions
• What is the role of biochemotherapy in the treat-
ment of metastatic malignant melanoma?
• What are the adverse effects and effects on quality
of life of biochemotherapy as a treatment option?
For the purposes of this report, “biochemotherapy”
is defined as a therapeutic regimen that includes, at a
minimum, chemotherapy (either single-agent or com-
bination) and interleukin-2.
Perspectives
Although early detection, appropriate surgery, and in
some cases adjuvant therapy have improved outcomes,
at least one third of patients with early-stage melano-
ma will develop metastases. Recently, in an effort to
potentially maximize outcomes, the combination of
chemotherapy and immunotherapy (biochemotherapy)
was evaluated. The level of interest that this approach
has generated, particularly with regard to the appa-
rently high response rates seen in this otherwise deva-
stating illness, was sufficient to merit closer exami-
nation by the Melanoma Disease Site Group (DSG) of
Cancer Care Ontario’s Program in Evidence-based
Care (PEBC).
Outcomes
Outcomes of interest include response rate, disease-
free survival, overall survival, quality of life, and inci-
dence of grades 3 and 4 toxicities.
Methodology
Evidence was selected and reviewed by three mem-
bers of the PEBC’s Melanoma DSG and by two meth-
odologists. The present practice guideline report was
reviewed and approved by the Melanoma DSG, which
comprises medical and radiation oncologists, surge-
ons, and dermatologists. External review by Ontario
practitioners was obtained through a mailed survey,
the results of which were incorporated into the prac-
tice guideline. Final approval of the original guide-
line report was obtained from the PEBC’s Report Ap-
proval Panel.
Results
Clinical recommendations were drafted based on the
evidence identified through a systematic review. The
practice guideline report with draft recommendations
was mailed to Ontario practitioners for external re-
view and to the Report Approval Panel. Feedback from
both groups was incorporated into this report to create
the final practice guideline.
Practice Guideline
The recommendations that follow apply to adult
patients with metastatic malignant melanoma.
Because of the inconsistent results of the available
studies with regard to benefit (response, time to pro-
gression, and survival) and consistently high toxicity
rates, biochemotherapy is not recommended for the treat-
ment of metastatic melanoma.PRACTICE GUIDELINE SERIES
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1. QUESTIONS
• What is the role of biochemotherapy in the treat-
ment of metastatic malignant melanoma?
• What are the adverse effects and effects on quality
of life of biochemotherapy as a treatment option?
For the purposes of this report, “biochemotherapy”
is defined as a therapeutic regimen that includes, at a
minimum, chemotherapy (either single-agent or com-
bination) and interleukin-2. Outcomes of interest in-
cluded response rate, disease-free survival, overall
survival, quality of life, and adverse events.
2. CHOICE OF TOPIC AND RATIONALE
The incidence of malignant melanoma has been in-
creasing steadily since the end of the 1950s. In 2006,
the number of new cases diagnosed in Canada was
estimated at 4500, with 880 deaths 1. Of those new
cases, 1910 were estimated to have been diagnosed in
Ontario, with 430 of the 880 estimated deaths occur-
ring in that province 1.
Although early detection, appropriate surgery, and
in some cases adjuvant therapy have improved out-
comes, at least one third of patients with early-stage
melanoma will develop metastases. The prognosis for
patients with metastatic melanoma remains dismal.
Numerous clinical trials have attempted to identify
potential treatments for those patients, but most have
failed to establish any single “best” modality. Systemic
approaches that have been evaluated sequentially to
date include cytotoxic chemotherapy (single agents and
multi-drug combinations) and immunotherapies, includ-
ing interferon-α (IFN) and interleukin-2 (IL-2).
Recently, in an effort to potentially maximize out-
comes, the combination of chemotherapy and immu-
notherapy (called “biochemotherapy”) has been evalu-
ated. A number of randomized clinical trials have been
completed, and their results have now been reported.
The level of interest generated by this approach, par-
ticularly with respect to the apparently high response
rates seen in an otherwise devastating illness, was suf-
ficient to merit closer examination by the Melanoma
Disease Site Group (DSG) of Cancer Care Ontario’s
Program in Evidence-Based Care (PEBC).
3. METHODS
3.1 Guideline Development
The present practice guideline report was developed
by the PEBC, using the methods of the practice guide-
lines development cycle 2. Evidence was selected and
reviewed by three members of the Melanoma DSG and
by two methodologists. Members of the Melanoma DSG
disclosed potential conflict of interest information.
This practice guideline is a convenient and up-to-
date source of the best available evidence on chemo-
therapy (either single-agent or combination) and IL-2
in the treatment of metastatic melanoma. The present
report was developed through systematic review, evi-
dence synthesis, and input from practitioners in On-
tario. The practice guideline is a companion to a sys-
tematic review published elsewhere 3. Both documents
are intended to promote evidence-based practice in On-
tario, Canada. The PEBC is editorially independent of
Cancer Care Ontario and the Ontario Ministry of Health
and Long-Term Care.
External review is obtained for all practice guide-
line reports through a mailed survey of Ontario practi-
tioners. The survey consists of items that address the
quality of the draft practice guideline report and rec-
ommendations, and that ask whether the recommen-
dations should serve as a practice guideline. Final ap-
proval of the practice guideline report is obtained from
the PEBC’s Report Approval Panel.
3.2 Literature Search Strategy
A systematic search of the MEDLINE, EMBASE, CANCER-
LIT, and Cochrane Library databases was conducted.
In addition, the proceedings of the annual meetings of
the American Society of Clinical Oncology were
searched for reports of newly completed trials. Ran-
domized controlled trials (RCTs), meta-analyses of
RCTs, evidence-based clinical practice guidelines, and
systematic reviews were eligible for inclusion if they
reported on at least one of the outcomes of interest.
4. RESULTS
Nine randomized controlled trials 4–13 of biochemothe-
rapy plus one systematic review with meta-analysis 14
were located and included in the systematic review.
Of the nine eligible trials, six compared various
regimens of chemotherapy with biochemotherapy 4–9,
two compared chemotherapy plus IFN with biochem-
otherapy 10,11, and one trial compared biochemothera-
py with a combination of IFN and IL-2 12. Dose and me-
thod of administration varied from trial to trial.
Seven of the nine trials reporting on response rate
provided statistical comparisons 4,7–13. Only two trials
reported statistically significant response rates favour-
ing treatment with biochemotherapy 8,12; five trials failed
to detect any significant differences. None of the nine
trials detected a statistically significant survival improve-
ment with biochemotherapy.
When data were pooled, biochemotherapy was supe-
rior to chemotherapy in response [relative risk (RR): 1.52;
95% confidence interval (CI): 1.24 to 1.87; p < 0.0001]
and delayed progression at 6 months (RR: 0.85; 95% CI:
0.75 to 0.96; p = 0.008), but not in decreased mortality at
12 months (RR: 0.98; 95% CI: 0.84 to 1.16; p = 0.85).VERMA et al.
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One study 15 evaluated quality of life in the patients
included in a RCT of biochemotherapy versus chemothera-
py 7. Overall quality of life significantly declined through
the 5th treatment cycle with biochemotherapy (p = 0.03).
Biochemotherapy is a toxic therapy, and patients
are likely to experience serious hematologic, gastro-
intestinal, cutaneous, and constitutional toxicities. In
addition, there are risks of cardiovascular toxicities such
as myocardial events and arrhythmias, hypotension,
capillary leak syndrome, hepatotoxicity, and renal tox-
icity. When treatment is conducted in the correct set-
ting, grades 3 and 4 toxicities appear to be manage-
able, and treatment-related death can be minimized.
5. DSG CONSENSUS PROCESS
The draft guideline and systematic review were ap-
proved by the Melanoma DSG in December 2006.
6. REPORT APPROVAL PANEL
6.1 Results
In January 2007, before the evidence-based report was
submitted for external review, the report was reviewed
and approved by the PEBC’s Report Approval Panel. The
Panel consists of two members, including an oncologist
with expertise in clinical and methodology issues. These
key concerns were raised by the Panel:
• Was there consistency in the biochemotherapy regi-
mens tested in the phase II trials that led to the re-
ported phase III trials?
• Might variation in the response rates across the
reported trials be related to different tumour res-
ponse evaluation criteria?
• Was it appropriate to use 12-month mortality data
for the meta-analysis, when the report Introduc-
tion indicates that median survival for this patient
group is 6–8 months?
• Does the Results section show inconsistency in
commenting on a survival trend in the Rosenberg
trial 3, which suggests some benefit with chemo-
therapy, but not in the Eton trial 4, which suggests
some benefit with biochemotherapy.
In addition, one member of the Panel suggested that
explicit statements about “policy-determining” outcomes
would be helpful. Because in the present case, the rel-
evant outcomes appear to be overall survival coupled with
treatment toxicity, the Panel also suggested a defining
statement to indicate that focus.
6.2 Modifications/Actions
In response to the Panel feedback, the Melanoma DSG
• acknowledged that an optimum regimen had not
been identified for biochemotherapy, and that the
regimens used in the phase II and phase III trials
had varied, generally corresponding with institutional
or organizational preferences.
• indicated that the criteria used to define tumour res-
ponse in most trials were those of the World Health
Organization (or a similar definition) and added a
brief statement to the Trial Descriptions section of
the systematic review to summarize those data.
• agreed that 11–12 months was a reasonable time
point for data pooling in meta-analysis, because the
median survival for most of the reported trials fell
close to that range. In addition, the pooled 6-month
survival data showed a result similar to that obtained
at 12 months, and that finding was indicated in the
Results section of the report.
• acknowledged the need for consistency in data pres-
entation and added a comment on the contrasting
results of the Eton trial 4 following the discussion of
the Rosenberg trial 3 results in the Results section
of the report.
• Finally, although the PEBC guidelines are consid-
ered in policy determination, the authors consid-
ered that their main purpose was to provide guid-
ance for clinicians, and they therefore did not wish to
comment on policy-determining outcomes. In deve-
loping the recommendations, all relevant outcomes
were considered, and the DSG felt that the current
wording of the recommendation accurately reflec-
ted that fact. The recommendation was therefore
not revised.
7. PRACTITIONER FEEDBACK
7.1 Methods
Following discussion and consensus, the Melano-
ma DSG circulated the clinical practice guideline and
systematic review to clinicians in Ontario for review
and feedback.
Feedback was obtained through a mailed survey
of 12 medical oncologists in Ontario. The survey con-
sisted of items evaluating the methods, results, and
interpretive summary used to inform the draft recom-
mendations and asking whether the draft recommen-
dations should be approved as a practice guideline.
Written comments were invited. The survey was
mailed on March 5, 2007. Follow-up reminders were
sent at 2 weeks (post card) and 4 weeks (complete
package mailed again). The Melanoma DSG reviewed
the results of the survey.
7.2 Results
From among the 12 surveys mailed, 5 responses were
received (42% response rate). Responses include
returned completed surveys, plus telephone, fax, and
e-mail responses. Of the practitioners who respon-
ded, 4 indicated that the report was relevant to their
clinical practice, and they completed the survey. Table IPRACTICE GUIDELINE SERIES
CURRENT ONCOLOGY—VOLUME 15, NUMBER 2
88
summarizes key results of the practitioner feedback
survey.
7.3 Summary of Written Comments
Only 1 respondent provided a written comment, which
confirmed agreement with the report.
8. PRACTICE GUIDELINE
The present report reflects the integration of feedback
obtained through the external review process with final
approval given by the Melanoma DSG and the PEBC’s
Report Approval Panel.
8.1 Target Population
The recommendations set out in the practice guide-
line apply to adult patients with metastatic malignant
melanoma.
8.2 Recommendations
Because of the inconsistent results of the available stud-
ies with regard to benefit (response, time to progres-
sion, and survival) and consistently high toxicity rates,
biochemotherapy is not recommended for the treatment
of metastatic melanoma.
9. PRACTICE GUIDELINE DATE
Completed April 2007. Practice guidelines developed by
the PEBC of Cancer Care Ontario are reviewed and up-
dated regularly. Please visit the PEBC section of the Can-
cer Care Ontario Web site (www.cancercare.on.ca/
index_practiceGuidelines.htm) for the full guideline re-
port and subsequent updates.
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